Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 59

Therapies RNA Protein Expression DNA 59

Drug Discovery World

APRIL 30, 2024

The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

NOVEMBER 9, 2023

Sandra Ergueta-Carballo, PhD, Project Coordinator, University of Cambridge, on: ‘Advancing snake envenomation treatment: designing the next generation of antivenoms’. Jorge Dias, PhD, Principal Scientist, Alchemab Therapeutics, on: ‘A patient-first approach to discover first-in-class antibody therapeutics’.

Engineering 130

Engineering Therapies Protein Production Science 130

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. based Mogrify Limited expanded its research collaboration with MRC Laboratory of Molecular Biology.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52